MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Depression"

  • 2023 International Congress

    Incidence of Parkinson’s disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort

    SJ. Chung, SH. Kang, S-J. Moon, M. Kang, GJ. Cho, S-B. Koh (Goyang, Republic of Korea)

    Objective: We aimed to investigate the incidence of Parkinson’s disease (PD) by age and year for each sex as well as the modifiable risk factors…
  • 2023 International Congress

    Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers

    C. Marras, D. Weintraub, J. Beck, A. Naito, Z. Meyer, N. Dahodwala, T. Davis, K. Mills, J. Miyasaki, S. Mantri, M. Neault, A. Brown, A. Allen, E. Nelson, H. Liu (Toronto, Canada)

    Objective: Implement depression screening using a validated instrument for people with Parkinson’s (PWP) as part of standard of care in the specialist movement disorders setting…
  • 2023 International Congress

    Risk of Depression after Parkinson’s disease, stroke, multiple sclerosis, and migraine in an Iranian population

    F. Hojjati Pour, M. Salari, H. Pakdaman, M. Etemadifar, N. Mirjamali, M. Khalkhali, A. Farahani (Teheran, Islamic Republic of Iran)

    Objective: We aim to evaluate the prevalence of depression in disorders including multiple sclerosis (MS), Parkinson's disease (PD), migraine, and stroke. Also, we detect risk…
  • 2023 International Congress

    Risk factors of sleep disordered breathing in Veterans with Parkinson’s disease.

    A. Sarwar (PEARLAND, USA)

    Objective: To investigate factors associated with the risk of sleep disordered breathing (SDB) in Veterans with Parkinson's disease (PD). Background: Sleep disordered breathing is common…
  • 2023 International Congress

    Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease

    S. Bordet, L. Grasso, L. Udovin, G. Chevalier, M. Otero-Losada, F. Capani, S. Perez-Lloret (Buenos Aires, Argentina)

    Objective: The aim of this study was to explore the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on…
  • 2023 International Congress

    Suicidal ideation and suicide risk in Parkinson’s disease

    J. Lam, X. Tang, D. Meng, J. Zhu, P. Uzelman, F. Pio, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To examine the prevalence of suicidal ideation and suicide risk in patients with Parkinson’s disease (PD) and to assess the relationship between suicidal ideation…
  • 2023 International Congress

    Pain as a Risk Factor for Developing Depression among Patients with Parkinson’s Disease: A Systematic Review of 1426 patients

    S. Mohammed, A. Eldeen (Sohag, Egypt)

    Objective: This systematic review aims mainly to investigate pain as an independent risk factor for developing depressive symptoms among patients with PD. Background: Parkinson's disease…
  • 2023 International Congress

    Increased incidence of Functional movement disorders during COVID-19 pandemic

    A. Cherian, D. Kalikavil Puthanveedu, N. Paramasivan, K. S (Thiruvananthapuram, India)

    Objective: To assess the frequency of functional movement disorders (FMD) during the COVID-19 pandemic in comparison to the pre-pandemic period and to identify factors causing…
  • 2023 International Congress

    Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)

    E. Bradley, K. Sakai, G. Fernandes, C. Ludwig, M. Bock, J. Ostrem, C. Tanner, A. O'Donovan, P. Finley, Z. Busby, A. Mckernan, R. Zuzuarregui, A. Penn, A. Wang, A. Theberge, R. Rosen, J. Woolley (San Francisco, USA)

    Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…
  • 2023 International Congress

    Habenula Volume in Mood Disorders in Parkinson’s Disease

    B. Samanci, Y. Temel, M. Kuijf, S. Tan, S. Michielse (Maastricht, Netherlands)

    Objective: To assess whether dysregulation of habenula (Hb) contributes to mood disorders in Parkinson’s disease (PD). Background: PD is often accompanied by mood disorders, such…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley